267 related articles for article (PubMed ID: 38216757)
1. Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician.
Szekanecz Z; Buch MH; Charles-Schoeman C; Galloway J; Karpouzas GA; Kristensen LE; Ytterberg SR; Hamar A; Fleischmann R
Nat Rev Rheumatol; 2024 Feb; 20(2):101-115. PubMed ID: 38216757
[TBL] [Abstract][Full Text] [Related]
2. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.
Mori S; Ogata F; Tsunoda R
Clin Rheumatol; 2021 Nov; 40(11):4457-4471. PubMed ID: 34554329
[TBL] [Abstract][Full Text] [Related]
3. [Janus kinase inhibitors].
Witte T
Z Rheumatol; 2022 Mar; 81(2):94-99. PubMed ID: 34820733
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.
Sung YK; Lee YH
J Clin Pharm Ther; 2021 Aug; 46(4):984-992. PubMed ID: 33600008
[TBL] [Abstract][Full Text] [Related]
5. Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports.
Goldman A; Galper BL; Druyan A; Grossman C; Sharif K; Shechtman L; Moshkovits Y; Lahat A; Ben-Zvi I
Semin Arthritis Rheum; 2024 Aug; 67():152461. PubMed ID: 38772185
[TBL] [Abstract][Full Text] [Related]
6. Are all JAK inhibitors for the treatment of rheumatoid arthritis equivalent? An adjusted indirect comparison of the efficacy of tofacitinib, baricitinib, upadacitinib, and filgotinib.
Vallez-Valero L; Gasó-Gago I; Marcos-Fendian Á; Garrido-Alejos G; Riera-Magallón A; Plaza Diaz A; Martinez-Molina C; Mangues-Bafalluy MA; Corominas H
Clin Rheumatol; 2023 Dec; 42(12):3225-3235. PubMed ID: 37831336
[TBL] [Abstract][Full Text] [Related]
7. Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study.
Yoshida S; Miyata M; Suzuki E; Kanno T; Sumichika Y; Saito K; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Asano T; Sato S; Migita K
Front Immunol; 2023; 14():1267749. PubMed ID: 37868999
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review.
Jegatheeswaran J; Turk M; Pope JE
Immunotherapy; 2019 Jun; 11(8):737-754. PubMed ID: 30955397
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box.
Misra DP; Pande G; Agarwal V
Clin Rheumatol; 2023 Feb; 42(2):621-632. PubMed ID: 36264400
[TBL] [Abstract][Full Text] [Related]
10. [Rheumatoid arthritis: Appraisement of the new security warnings for JAK-inhibitors].
Fiehn C
Dtsch Med Wochenschr; 2024 Mar; 149(6):326-330. PubMed ID: 38412990
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs.
Lee YH; Song GG
Z Rheumatol; 2021 May; 80(4):379-392. PubMed ID: 32367211
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naïve patients with rheumatoid arthritis.
Sung YK; Lee YH
Z Rheumatol; 2021 Nov; 80(9):889-898. PubMed ID: 32970188
[TBL] [Abstract][Full Text] [Related]
13. Upadacitinib for the Treatment of Rheumatoid Arthritis: An Extensive Review.
Boyce EG; Rogan EL; C Lui M
Ann Pharmacother; 2023 Apr; 57(4):450-462. PubMed ID: 35919945
[TBL] [Abstract][Full Text] [Related]
14. JAK Inhibitors: What Is New?
Reddy V; Cohen S
Curr Rheumatol Rep; 2020 Jul; 22(9):50. PubMed ID: 32700001
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular safety, cancer and Jak-inhibitors: Differences to be highlighted.
Benucci M; Damiani A; Infantino M; Manfredi M; Lari B; Grossi V; Gobbi FL; Sarzi-Puttini P
Pharmacol Res; 2022 Sep; 183():106359. PubMed ID: 35907434
[TBL] [Abstract][Full Text] [Related]
16. Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study.
Scheepers L; Yang Y; Chen YL; Jones G
Semin Arthritis Rheum; 2024 Feb; 64():152314. PubMed ID: 38029717
[TBL] [Abstract][Full Text] [Related]
17. Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicentre cohort study.
Uchida T; Iwamoto N; Fukui S; Morimoto S; Aramaki T; Shomura F; Aratake K; Eguchi K; Ueki Y; Kawakami A
Rheumatology (Oxford); 2023 Oct; 62(10):3358-3365. PubMed ID: 36794922
[TBL] [Abstract][Full Text] [Related]
18. Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
Scott IC; Hider SL; Scott DL
Drug Saf; 2018 Jul; 41(7):645-653. PubMed ID: 29500799
[TBL] [Abstract][Full Text] [Related]
19. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis.
Sepriano A; Kerschbaumer A; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; McInnes IB; Bijlsma JW; Burmester GR; de Wit M; Falzon L; Landewé R
Ann Rheum Dis; 2020 Jun; 79(6):760-770. PubMed ID: 32033941
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
Ho Lee Y; Gyu Song G
J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
